ArticleThe Journal of investigative dermatology2015
Human mitochondrial NAD(P)(+)-dependent malic enzyme participates in cutaneous melanoma progression and invasion.
Article in The Journal of investigative dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 49 citations in OpenAlex.
- NADPH-Related Enzymes and Cancer: Facts and Insights Into the Application of Immunohistochemistry.Biochemistry research international · 2026Review
- Interplay between malic enzyme 2, de novo serine synthesis, and the malate-aspartate shuttle drives metabolic adaptation in triple-negative breast cancer.Cancer & metabolism · 2025Article
- Malic enzymes in cancer: Regulatory mechanisms, functions, and therapeutic implications.Redox biology · 2024Review
- Overexpression of malic enzyme is involved in breast cancer growth and is correlated with poor prognosis.Journal of cellular and molecular medicine · 2024Article
- Targeting human mitochondrial NAD(P)Cellular oncology (Dordrecht, Netherlands) · 2023Article
- Suppression of the human malic enzyme 2 modifies energy metabolism and inhibits cellular respiration.Communications biology · 2023Article
- ME2 Promotes Hepatocellular Carcinoma Cell Migration through Pyruvate.Metabolites · 2023Article
- In the Quest for Potent and Selective Malic Enzyme 3 Inhibitors for the Treatment of Pancreatic Ductal Adenocarcinoma.ACS medicinal chemistry letters · 2023Article
- Integrative structural and functional analysis of human malic enzyme 3: A potential therapeutic target for pancreatic cancer.Heliyon · 2022Article
- Redox regulation of the immune response.Cellular & molecular immunology · 2022Review
- Extracellular citrate and metabolic adaptations of cancer cells.Cancer metastasis reviews · 2021Review
- Mitochondrial malic enzyme 2 promotes breast cancer metastasis via stabilizing HIF-1α under hypoxia.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2021Article
- Review
- Article
- ME2 Promotes Proneural-Mesenchymal Transition and Lipogenesis in Glioblastoma.Frontiers in oncology · 2021Article
- NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications.Signal transduction and targeted therapy · 2020Review
- The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression.Oncogene · 2020Article
- The interplay between oxidative stress and bioenergetic failure in neuropsychiatric illnesses: can we explain it and can we treat it?Molecular biology reports · 2020Review
- Functional Roles of Metabolic Intermediates in Regulating the Human Mitochondrial NAD(P)Scientific reports · 2019Article
- Urea transport B gene induces melanoma B16 cell death via activation of p53 and mitochondrial apoptosis.Cancer science · 2018Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous melanoma is the most life-threatening neoplasm of the skin, accounting for most of the skin cancer deaths. Accumulating evidence suggests that targeting metabolism is an appealing strategy for melanoma therapy. Mitochondrial NAD(P)(+)-dependent malic enzyme (ME2), an oxidative decarboxylase, was evaluated for its biological significance in cutaneous melanoma progression. ME2 mRNA and protein expression significantly increased during melanoma progression, as evidenced by Gene Expression Omnibus analysis and immunohistochemistry on clinically annotated tissue microarrays, respectively. In addition, ME2 knockdown attenuated melanoma cell proliferation in vitro. ME2 ablation resulted in reduced cellular ATP levels and elevated cellular reactive oxygen species production, which activated the AMP-activated protein kinase pathway and inhibited acetyl-CoA carboxylase. Furthermore, ME2 expression was associated with cell migration and invasion. ME2 knockdown decreased anchorage-independent growth in vitro and tumor cell growth in vivo. These results suggested that ME2 might be an important factor in melanoma progression and a novel biomarker of invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.